Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22 oct. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
28 août 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05 août 2019 16h05 HE
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerInitiated Phase 1/2a clinical trial for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
31 juil. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 08h30 HE
|
Harpoon Therapeutics
Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerNet proceeds of approximately $71 million from completion...
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
18 avr. 2019 07h30 HE
|
Harpoon Therapeutics
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...
Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference
13 mars 2019 16h07 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results
07 mars 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
Harpoon Therapeutics to Present at SVB Leerink Global Healthcare Conference
20 févr. 2019 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...